Phase 3b study of degarelix for intermittent therapy of advanced prostate cancer

Ferring Pharmaceuticals announced the launch of a Phase 3b clinical trial of degarelix (gonadotropin-releasing hormone receptor antagonist) for injection as an intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer.  The study will compare IADT to continuous androgen deprivation therapy (ADT) for 14 months with either leuprolide or degarelix in patients who have rising serum prostate-specific antigen (PSA) levels after previous curative therapies. The trial evaluates whether IADT minimizes the negative effects of ADT and maximizes quality of life, while maintaining tumor response as measured by PSA suppression.

Degarelix is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved for the treatment of hormone sensitive advanced prostate cancer.

For more information call (888) FERRING or visit